HIF1A — LLMpedia

Contents

HIF1A HIF1A is the gene encoding hypoxia-inducible factor 1-alpha, a transcription factor central to cellular responses to reduced oxygen tension, with critical roles in Nobel Prize in Physiology or Medicine-level research on hypoxia, United States National Institutes of Health, Max Planck Society-supported studies, and translational work at institutions like Harvard Medical School and Johns Hopkins University. It is studied across model systems including Mus musculus, Drosophila melanogaster, and Caenorhabditis elegans and features in clinical research at centers such as Mayo Clinic and Memorial Sloan Kettering Cancer Center. HIF1A links to pathways investigated by groups at Cold Spring Harbor Laboratory, Broad Institute, and European Molecular Biology Laboratory.

Structure and Isoforms

HIF1A encodes a protein with basic helix-loop-helix (bHLH) and Per-Arnt-Sim (PAS) domains, described in structural analyses from teams at Stanford University, University of Cambridge, and California Institute of Technology using techniques refined at European Synchrotron Radiation Facility. Crystal and NMR studies reported by investigators affiliated with Max Planck Institute and University of Oxford delineate the bHLH domain that mediates DNA binding and dimerization with partners such as Aryl hydrocarbon receptor nuclear translocator. Alternative splicing and proteolytic processing produce isoforms documented in datasets from Ensembl and UniProt, with isoform-specific studies from Yale University and University of Toronto showing differential transcriptional activity and stability in contexts like European Union-funded hypoxia consortia. Comparative genomics across databases maintained at National Center for Biotechnology Information and Wellcome Sanger Institute reveals conserved residues implicated in oxygen sensing and protein interactions noted by researchers at ETH Zurich and Karolinska Institutet.

HIF1A functions as a heterodimeric transcription factor that, upon heterodimerization with partners characterized in seminal work from Massachusetts Institute of Technology and University of California, San Francisco, binds hypoxia response elements in promoters studied in reports from Cell Press and Nature Publishing Group. Its mechanism integrates oxygen-dependent prolyl hydroxylation characterized by researchers at Rockefeller University and University of Pennsylvania, facilitating recognition by ubiquitin ligases exemplified by complexes studied at University of Cambridge and Scripps Research. Downstream effects on angiogenesis, glycolysis, and erythropoiesis are described in clinical and basic research from UCSF Medical Center, Imperial College London, and Johns Hopkins School of Medicine, and link to processes investigated at World Health Organization-collaborating centers dealing with ischemia and tumor biology.

Regulatory control of HIF1A includes oxygen-dependent hydroxylation by prolyl hydroxylase domain enzymes reported by groups at Karolinska Institutet and University of Copenhagen, and asparaginyl hydroxylation mediated by enzymes studied at Max Planck Institute for Biochemistry. The von Hippel–Lindau tumor suppressor complex, elucidated through landmark studies at Yale University and University of Zurich, ubiquitinates HIF1A under normoxia leading to proteasomal degradation characterized in work from Princeton University and Cold Spring Harbor Laboratory. Additional modifications such as phosphorylation and acetylation have been reported by investigators at McGill University and University of Michigan, modulating interactions with coactivators like CREB-binding protein and influencing transcriptional programs explored at Dana-Farber Cancer Institute.

HIF1A drives developmental and physiological programs including vascular remodeling, metabolic switching, and stem cell niche regulation documented in developmental biology studies from University of Cambridge, Harvard University, and Max Planck Institute for Developmental Biology. Its role in embryogenesis and placentation is reported by perinatal research groups at University College London and Karolinska University Hospital, while studies at University of California, Berkeley and Stanford University link HIF1A activity to adaptations in high-altitude populations investigated by expeditions to Tibet and Andes Mountains involving collaborations with Smithsonian Institution researchers. In immunity and inflammation, HIF1A influences responses characterized by teams at Pasteur Institute and Fred Hutchinson Cancer Research Center.

Aberrant HIF1A activity contributes to tumor progression, metastasis, and therapeutic resistance documented extensively in oncology centers like Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and National Cancer Institute. Mutations and dysregulation intersect with hereditary syndromes described in clinical genetics services at Mayo Clinic and Cleveland Clinic, and influence outcomes in ischemic diseases studied at Mount Sinai Hospital and Guy's and St Thomas' NHS Foundation Trust. Pharmacological targeting of HIF1A pathways has led to clinical trials coordinated by networks including European Medicines Agency and Food and Drug Administration, with investigational agents developed by biotechnology companies collaborating with GlaxoSmithKline and Roche.

HIF1A interacts with an array of cofactors and signaling molecules mapped in proteomic atlases produced by ProteomeXchange and laboratories at Broad Institute and European Bioinformatics Institute, including dimerization partners and chromatin remodelers identified in studies at Johns Hopkins University and University of California, San Diego. Well-characterized transcriptional targets include genes involved in glycolysis, angiogenesis, and iron metabolism highlighted in research from Imperial College London, Karolinska Institutet, and University of Sydney, with specific promoters and enhancers profiled in epigenomic consortia such as ENCODE and Roadmap Epigenomics Project. Network analyses by teams at MIT and University of Chicago integrate HIF1A-regulated modules with signaling cascades studied in translational research at Vanderbilt University and University of Illinois at Chicago.

Category:Transcription factors Category:Human genes Category:Hypoxia